Drug Trial Radar · NCT01453153
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Sep 2011
Primary completion
Feb 2014
Study completion May 2015
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated pancreatic cancer patients. Phase 2: Randomized, double blind study to compare the effect of overall survival of gemcitabine plus PEGPH20 vs gemcitabine plus placebo in Stage IV previously untreated pancreatic cancer patients.
Conditions
- Stage IV Pancreatic Cancer
Interventions
GemcitabineDrug
1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
PEGPH20Drug
(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
PlaceboDrug
(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Dose-limiting Toxicity (DLT)Time frame: first 4 weeks of Cycle 1
- Recommended Phase 2 Dose (RP2D)Time frame: first 4 weeks of Cycle 1
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
California Pacific Medical Center
San Francisco, California
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
UMDNJ - New Jersey Medical School
Newark, New Jersey
NSLIJ Health System, Monter Cancer Center
New Hyde Park, New York
Mount Sinai School of Medicine
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Seattle Cancer Care Alliance
Seattle, Washington
Chelyabinsk Regional Clinical Oncology Center
Chelyabinsk, Russia
Russian Oncological Research Center n.a. N.N. Blokhin
Moscow, Russia
Medical Radiological Research Center
Obninsk, Russia
Omsk Regional Budget Medical Institution
Omsk, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.